We are asking our members to help us understand how TTS can better serve you!
Take the TTS 2021 Needs Assessment Survey.
Results of the survey will directly impact TTS activities!
Participate by: February 15, 2021Click here to take the survey
Recently, a new SARS-CoV-2 lineage called B.1.1.7 (variant of concern: VOC 202012/01) emerged in the United Kingdom that was reported to spread more efficiently and faster than other strains. This variant has an unusually large number of mutations with 10 amino acid changes in the spike protein, raising concerns that its recognition by neutralizing antibodies may be affected. This article tested SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 40 participants who were vaccinated in a previously reported trial with the mRNA-based COVID-19 vaccine BNT162b2. The immune sera had slightly reduced but overall largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus. These data indicate that the B.1.1.7 lineage will not escape BNT162b2-mediated protection.
This review article compiled all therapeutic mAbs targeting cytokine storm, which are in clinical trials for its repurposing in the management of COVID-19. Compilation of clinical trial data indicated that therapeutic monoclonal antibodies targeting interleukins (IL-6, IL-1ra, IL-8, IL-1β, IL-17A, IL-33), interferon-gamma, tumor necrosis factor-alpha, P-selectin, connective tissue growth factor, plasma kallikrein, tumor necrosis factor superfamily 14, granulocyte macrophage colony stimulating factor, colony stimulating factor 1 receptor, C-C chemokine receptor type 5, cluster of differentiation 14 and 147, vascular endothelial growth factor, programmed cell death protein-1, Angiopoietin - 2, human factor XIIa, complementary protein 5, natural killer cell receptor G2A, human epidermal growth factor receptor 2, immunoglobulin-like transcript 7 receptor, complement component fragment 5a receptor and viral attachment to the human cell were under investigation for management of severely ill patients with COVID-19. Among these, about 65 clinical trials are targeting IL-6 inhibition as the most promising one and Tocilizumab, an IL-6 inhibitor is considered to be the potential candidate to treat cytokine storm associated with the COVID-19.
An issue for a northern winter or the southern summer sun! Perhaps an issue to kick start your research with ideas from these papers. Young women with renal transplants at risk of cardiac disease, A new antibody to treat ABMR. An RCT or two and some important papers on the heart in Liver transplantation and management of Lung transplantation. A great review of the role of NK cells and also some important reflections on multi drug resistant organisms.
The Editors of Transplantation and Transplantation Direct are seeking expressions of interest for the role of Editorial Fellow.
The Fellowship is designed for an early career professional in transplantation interested in being on the frontlines of Transplantation, the most cited journal in transplantation, and Transplantation Direct, our open access journal.
The participant will identify the impact of clinical research on patient outcomes in the area of transition from hospital to home and chronic illness care for parents of pediatric solid organ transplant recipients.
Thursday February 25th 2021
Dear Women in Transplantation and TTS members,
The Asian Society of Transplantation (AST - myasot.org) in collaboration with the TTS Women in Transplantation (WIT) initiative are hosting two webinars on Gender Disparity in Transplant in Asia.
Thursday, January 28, 2021 (19:00 Seoul / Tokyo time - GMT+9)
Women in Transplantation (WIT) initiative of The Transplantation Society will provide funding to an Early Career Researcher to support research focusing on sex and gender issues relevant to solid organ transplantation.
This initiative was made possible with support with One Lambda, a Thermo Fisher Scientific brand, and Sanofi, with each supporting one award.
The spectrum of studies includes basic, clinical and translational. This individual should have spent two years or less performing research relevant to solid organ transplantation since obtaining their last degree (PhD, MD, MSc, PharmD, or equivalent). This work may represent a continuation of current research or a novel aspect of work. The mentor should have expertise in transplantation or immunology but need not be an investigator with known expertise in gender or sex.
Jan. 22 - An Icelandic man who got the world’s first double-shoulder-and-arm transplant is recovering well after the operation, two decades after the accident that cost him both limbs, doctors have said.
Jan. 27 - According to investigators, a lack of definitive knowledge about the presence of SARS-CoV-2 in corneal tissues has resulted in the recommendation to avoid using corneal tissue for transplantation when the tissue was obtained from donors with COVID-19 that had been confirmed or those who were exposed to COVID-19.
Jan. 25 - In older patients with myelodysplastic syndrome (MDS) and a suitable HLA-matched donor, hematopoietic cell transplantation (HCT) improves survival even among those with high-risk features, according to a multicenter study that included a control group.
Jan. 27 - A characteristic feature of all stem cells is their ability to self-renew. But how is this potential maintained throughout life? Scientists at the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine* (HI-STEM) have now discovered in mice that cells in the so-called "stem cell niche" are responsible for this: Blood vessel cells of the niche produce a factor that stimulates blood stem cells and thus maintains their self-renewal capacity. With the decades of life, the production of this factor ceases and blood stem cells begin to age.
Jan. 28 - Patients categorized as frail and who were undergoing evaluation for kidney transplantation were “more likely” to have care partners who were also frail, according to a study.